Elsevier

Experimental Cell Research

Volume 237, Issue 1, 25 November 1997, Pages 46-54
Experimental Cell Research

Regular Article
Induction and Expression of Human Cartilage Glycoprotein 39 in Rheumatoid Inflammatory and Peripheral Blood Monocyte-Derived Macrophages

https://doi.org/10.1006/excr.1997.3764Get rights and content

Abstract

Human cartilage glycoprotein 39 (HC gp-39) has been described as a major secreted product of cultured articular chondrocytes, synovial fibroblasts, and the osteosarcoma line MG63. However, its expression in these cells types has not been directly linked to corresponding cell typesin vivo.In this report, expression of HC gp-39 is demonstrated from peripheral blood-derived macrophages in association with their differentiation from monocytes to macrophages. Consistent with macrophage specificity, HC gp-39 expression is also induced upon selective stimulation of the pluripotent promyelocytic leukemia cell line HL-60 toward the monocyte/macrophage lineage with vitamin D3or phorbol 12-myristate 13-acetate (PMA), while treatments stimulating granulocyte and eosinophilic pathways do not induce expression. Furthermore, HC gp-39 expression levels correlate with the degree of morphological differentiation induced by PMA and vitamin D3treatments. PMA-induced mRNA expression occurs by 36 h and is a secondary transcriptional response since its synthesis is inhibited by cycloheximide. Apparently, HC gp-39 expression is tied to later events in the differentiation of monocytes into macrophages. Thein vivosignificance of these results is validated by thein situdetection of HC gp-39 mRNA in inflammatory macrophages associated with rheumatoid synovium. Thus, macrophages appear to be an important source of HC gp-39, which has been shown to be present at elevated levels in the blood and synovium of rheumatoid arthritis patients. The implications of this extend well beyond the previously restricted observations in cell types associated with the joint and suggest a potential involvement of macrophage-derived HC gp-39 in other aspects of inflammation, tissue remodeling, and host defense.

References (34)

  • R.W. Meier et al.

    The induction kinetics of Il-8 messenger RNA in HL60 cells demonstrate the participation of negative-acting gene(s)

    Leukocyte Res.

    (1995)
  • M. Castagna et al.

    Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters

    J. Biol. Chem.

    (1982)
  • J.P. van Leeuwen et al.

    Evidence for the functional involvement of protein kinase C in the action of 1,25-dihydroxyvitamin D3 in bone

    J. Biol. Chem.

    (1992)
  • J.S. Johansen et al.

    Serum YKL-40: A new potential marker of prognosis and location of metastases of patients with recurrent breast cancer

    Eur. J. Cancer A

    (1995)
  • P. Nyirkos et al.

    Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period

    Biochem. J.

    (1990)
  • J.S. Johansen et al.

    Identification of proteins secreted by human osteoblastic cells in culture

    J. Bone Miner. Res.

    (1992)
  • Cited by (111)

    • Hippocampal YKL-40 expression in rats after status epilepticus

      2016, Epilepsy Research
      Citation Excerpt :

      Human cartilage glycoprotein 39 (HC-gp39), or YKL-40, is a recently identified inflammatory protein that belongs to the glycosyl hydrolases family 18. YKL-40 represents a major secreted product of activated macrophages, neutrophils, vascular smooth muscle cells, chondrocytes, synoviocytes and tumor cells (Johansen, 2006; Kirkpatrick et al., 1997; Rehli et al., 2003). However, its function remains unclear.

    • Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction

      2015, Clinical Immunology
      Citation Excerpt :

      Only chitotriosidase (CHIT-1) and acidic mammalian chitinase (AMCase) have demonstrated a chitinolytic activity, while chitinase-like proteins can bind chitin, but do not have chitinolytic activity [1]. CHI3L1 is produced by a variety of cells including chondrocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, hepatic stellate cells, airway epithelial cells, neutrophils, inflammatory macrophages and different types of cancer cells [2–9]. Regarding the central nervous system (CNS), its expression has also been described in astrocytes and microglia of encephalitic monkeys and human immunodeficiency virus encephalitis patients as well as in samples of human brain infarction [10,11].

    View all citing articles on Scopus
    1

    To whom correspondence and reprint requests should be addressed at Department of Gene Expression Sciences, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406. Fax: (610) 270-5093.

    2

    Current address: Division of Anti-infectives, SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426.

    View full text